Ignite Creation Date:
2024-05-06 @ 7:31 PM
Last Modification Date:
2024-10-26 @ 3:08 PM
Study NCT ID:
NCT06046794
Status:
RECRUITING
Last Update Posted:
2023-12-21
First Post:
2023-09-06
Brief Title:
Efficacy of First-Line Gemcitabine Chemotherapy in GemCore Metastatic Pancreatic Adenocarcinoma Patients
Sponsor:
Institut Paoli-Calmettes
Organization:
Institut Paoli-Calmettes
Study Overview
Official Title:
Phase IV Study Assessing Efficacy of First-Line Chemotherapy With Gemcitabine in GemCore Metastatic Pancreatic Adenocarcinoma Patients Ineligible to FOLFIRINOX Treatment
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GemSign-01
Brief Summary:
The goal of this interventional study is to learn about the efficacy of first-line chemotherapy with Gemcitabine in metastatic pancreatic adenocarcinoma patients expressing the GemCore signature in their tumor The main question it aims to answer is to assess efficacy of Gemcitabine tumor response survival rate in the population of patient bearing the GemCore signature
Participants will start the chemotherapy with Gemcitabine as usually performed in standard care of their center They will consent to a genomic analyze of their tumor to know if it bears the GemCore signature The center will manage the participants follow up as usually realized in standard care
Participants will start the chemotherapy with Gemcitabine as usually performed in standard care of their center They will consent to a genomic analyze of their tumor to know if it bears the GemCore signature The center will manage the participants follow up as usually realized in standard care
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None